Navigation Links
New Race –Specific drug

World's first race-specific medicine has been developed to resolve the controversy over// whether black people are genetically different from whites.

BiDil, a drug combination for treating heart failure, has proved three times more effective in black patients than it has for their white counterparts, its manufacturer claims. If approved by the FDA, it would be the first drug ever to be licensed for use by a single ethnic group.

The results of clinical trials are testament to BiDil's value. In trials, it improved survival rates among black people who had suffered heart failure by 47 per cent. In white patients, the figure was only 15 per cent.

BiDil works by boosting the level of nitrous oxide in the walls of the body's arteries and capillaries, allowing them to expand and thereby reducing the body's blood pressure. In turn, this reduces overall strain on the heart. It proved more effective in African-American patients because they have naturally lower levels of nitrous oxide in their blood and long-term high blood pressure is usually the cause of heart failure.

In contrast, the leading causes of heart failure among white people are clogged arteries and damage to the cardiac muscle caused by previous heart attacks. The issue of whether biological differences can be determined by one's ethnic origins is a long-standing one, and it raises a number of legal and ethical questions. There is a powerful lobby which is in favour of racial profiling when it comes to drug development, backed by evidence that suggests a degree of truth in the ethnicity theory. The reasons for the difference in response to a drug are unclear although it is thought that genes play a major role.

Type-2 diabetes is more common among people from the Indian subcontinent and is thought to be due to a combination of genetic factors and environmental ones. It has also been shown that cases of increased heart weight - an abnormality that can cause heart attacks, heart failure and stroke - is up to three times more prevalent among African-Americans than whites. These exciting results suggest the extent to which even the early stages of heart disease could be prevented in the African-American community by prevention and treatment of hypertension.


'"/>




Related medicine news :

1. Dr Reddy’s Laboratories to challenge patents on drug
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has ... chances of acceptance to a residency in a United States hospital. Being accepted ... the U.S. , According to data released by the ECFMG®, every year, 50 ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon ... the signature product of her research center at Bio-Logic Aqua Research® Water Life ... and the greatest number of sufferers of blindness. “We think that Nature’s Tears® ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the ... from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related ... though activity levels decline over time. The study, presented today at the ...
(Date:7/21/2017)... ONTARIO, CANADA (PRWEB) , ... July 21, 2017 ... ... give insight into why concussion rates are on the rise, say researchers presenting ... Meeting today in Toronto, Ontario, Canada. , “The combination of evaluating the patterns ...
(Date:7/20/2017)... ... 2017 , ... ChenMed , a leading provider of value-based care for ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family ... of Ambulatory Services for the UVA Health System, brings 30 years of highly relevant ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July ... UTHR ) announced today that it will report ... opens on Thursday, July 27, 2017. ... on Thursday, July 27, 2017, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based ... today announced the completion of a $12.7 million Series A ... as well as the participation of existing investors. ... the support of New Ventures III and our current investors, ... the potential of our platform technology to transform the course ...
Breaking Medicine Technology: